FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

Tesamorelin

Egrifta / TH9507

Growth Hormone Secretagogues

Tesamorelin (trade name Egrifta) is a synthetic growth hormone-releasing hormone (GHRH) analog consisting of the full 44-amino-acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability and receptor binding. It is the only FDA-approved GHRH analog, specifically indicated for the reduction of excess abdominal/visceral fat in HIV-infected patients with lipodystrophy. Its mechanism stimulates pulsatile endogenous GH release from the pituitary gland, preserving normal physiological feedback regulation unlike exogenous GH administration.

작용 메커니즘

Synthetic GHRH analog with a trans-3-hexenoic acid modification for enhanced stability. Specifically targets visceral adipose tissue reduction via GH-mediated lipolysis. FDA-approved mechanism preserves physiologic GH pulsatility and IGF-1 negative feedback.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

FDA-approved protocol: 2mg daily via subcutaneous injection. Research protocols follow the same dosing. Administered at a consistent time daily, typically in the morning.

연구 노트

Clinical Research Status

Tesamorelin received FDA approval in November 2010 for the treatment of HIV-associated lipodystrophy and is marketed by Theratechnologies as Egrifta and Egrifta SV (single-vial formulation). Multiple Phase III clinical trials (including the landmark studies with over 800 HIV patients) demonstrated statistically significant visceral adipose tissue reduction of approximately 15-18% over 26 weeks. Ongoing research explores applications in non-alcoholic fatty liver disease (NAFLD), cognitive decline in aging and HIV, and broader metabolic syndrome indications beyond the HIV population.

Key Published Findings

Pivotal trials demonstrated that tesamorelin 2mg daily subcutaneous injection reduced visceral adipose tissue by a mean of 15.2% versus placebo over 26 weeks, with continued maintenance of reduction over 52 weeks of treatment. A landmark study published in Neurology showed tesamorelin improved cognitive function in older adults with mild cognitive impairment or subjective cognitive complaints, suggesting neuroprotective properties mediated through GH/IGF-1 signaling. Research has also demonstrated improvements in liver fat content and NAFLD biomarkers, with hepatic fat reduction of approximately 35% in HIV patients with fatty liver.

Safety Profile

Tesamorelin is generally well-tolerated with the most common adverse effects being injection site reactions (erythema, pruritus, pain) reported in approximately 8-13% of clinical trial participants. Fluid retention, arthralgia, and paresthesias occur at rates slightly above placebo, consistent with physiological GH elevation. The compound is contraindicated in pregnancy, patients with active malignancy, and those with disruption of the hypothalamic-pituitary axis, and carries warnings regarding potential glucose intolerance.

Drug Interactions & Contraindications

Tesamorelin may reduce the efficacy of cortisol replacement therapy by increasing cortisol-binding globulin, and patients on glucocorticoid replacement should be monitored. It should be used cautiously with drugs affecting glucose metabolism (insulin, oral hypoglycemics) as GH elevation can impair insulin sensitivity. The compound is contraindicated in patients with active malignancy due to the proliferative effects of elevated GH/IGF-1, and patients with a history of hypothalamic-pituitary tumors should not use it.

Comparison to Related Compounds

Unlike synthetic GH (somatropin) which provides a constant supraphysiological GH level, tesamorelin preserves the natural pulsatile pattern of GH release and maintains hypothalamic-pituitary feedback, resulting in a more physiological GH profile. Compared to CJC-1295 (a modified GHRH analog popular in peptide research), tesamorelin has the advantage of FDA approval, extensive clinical trial data, and insurance coverage for qualifying HIV patients. Sermorelin is a shorter GHRH fragment (1-29) with similar mechanism but lower potency and shorter half-life, requiring more frequent dosing.

Community Observations

Practitioners and patients report that the visceral fat reduction becomes measurable on DEXA scans within 3-4 months, with peak effects at 6-9 months of consistent daily use. The research and TRT community has adopted tesamorelin for its GH-elevating effects beyond the HIV population, noting improvements in sleep quality, body composition, and skin quality. Users frequently note that results reverse within 3-6 months of discontinuation, indicating the need for ongoing treatment, and many physicians prescribe it alongside testosterone replacement therapy for synergistic metabolic benefits.

반감기

~26-38 minutes

재조성

Sterile water (provided with kit)

보관

건조한 상태

Refrigerate 2-8C. Protect from light.

재조성된 상태

Use immediately after reconstitution. Discard unused portion.

미국 법적 상태

FDA-approved (Rx only)

또는 알려진 이름으로

EgriftaTH9507

자주 묻는 질문

Tesamorelin란 무엇인가요?

Tesamorelin (trade name Egrifta) is a synthetic growth hormone-releasing hormone (GHRH) analog consisting of the full 44-amino-acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability and receptor binding. It is the only FDA-approved GHRH analog, specifically indicated for the reduction of excess abdominal/visceral fat in HIV-infected patients with lipodystrophy. Its mechanism stimulates pulsatile endogenous GH release from the pituitary gland, preserving normal physiological feedback regulation unlike exogenous GH administration.

Tesamorelin는 어떻게 작용하나요?

Synthetic GHRH analog with a trans-3-hexenoic acid modification for enhanced stability. Specifically targets visceral adipose tissue reduction via GH-mediated lipolysis. FDA-approved mechanism preserves physiologic GH pulsatility and IGF-1 negative feedback.

Tesamorelin의 미국 규제 현황은 어떤가요?

FDA-approved (Rx only)

Tesamorelin의 반감기는 얼마인가요?

~26-38 minutes

Tesamorelin의 다른 이름은 무엇인가요?

Egrifta, TH9507

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기